The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2021 | Chemo-immunotherapy in patients with locally advanced gastroesophageal cancer
Thierry Alcindor, MD, MSc, McGill University Health Centre, Montreal, Canada, discusses the results of a study that aimed to assess the efficacy of combining immunotherapy with perioperative chemotherapy in treating patients with locally advanced gastroesophageal cancer. In this study, chemoimmunotherapy demonstrated encouraging improvements compared to chemotherapy alone. Dr Alcindor concludes by highlighting that future research is needed to further understand the benefits of this combined therapy. This interview was conducted at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
